Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event TranscriptSeeking Alpha • 06/13/26
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell DiseaseGlobeNewsWire • 06/13/26
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder CandidateZacks Investment Research • 06/02/26
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology TranscriptSeeking Alpha • 06/01/26
Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenibProactive Investors • 06/01/26
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor CevidoplenibGlobeNewsWire • 06/01/26
Why Is Agios Pharmaceuticals (AGIO) Up 8.6% Since Last Earnings Report?Zacks Investment Research • 05/29/26
Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic SyndromesGlobeNewsWire • 05/29/26
Avanzanite Bioscience's Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with ThalassaemiaBusiness Wire • 05/22/26
Agios' PYRUKYND® (mitapivat) Approved in the European Union for Adults with ThalassemiaGlobeNewsWire • 05/22/26
Agios Pharmaceuticals Touts Strong AQVESME Launch as Sickle Cell Filing AdvancesMarketBeat • 05/19/26
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell DiseaseZacks Investment Research • 05/13/26
Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell DiseaseGlobeNewsWire • 05/12/26
Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic AnemiasGlobeNewsWire • 05/12/26
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug MomentumZacks Investment Research • 04/30/26
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 04/29/26
Agios Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewsWire • 04/29/26
Earnings Preview: Agios Pharmaceuticals (AGIO) Q1 Earnings Expected to DeclineZacks Investment Research • 04/22/26
Agios Stock Sinks 23% as NVO's PKR Activator Meets Goal in SCD StudyZacks Investment Research • 04/21/26